The US Food and Drug Administration took a second unprecedented step in spurring development of OTC naloxone products by publishing a notice identifying data and other information needed in new drug applications for nonprescription access.
In a notice published on 15 November requesting comments, the agency signals that it is becoming assured about making naloxone available OTC, so much so that firms with approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?